Puma Biotechnology, Inc. (PBYI) AI Stock Analysis

Puma Biotechnology, Inc. is a biopharmaceutical company headquartered in Los Angeles, California, dedicated to advancing cancer care. Founded in 2010, the company develops and commercializes therapies for unmet oncology needs, centered on drug candidates such as PB272 neratinib. This oral treatment addresses early-stage HER2-overexpressed breast cancer and is evaluated with capecitabine for advanced HER2-positive breast cancer and HER2 mutation-positive solid tumors. Puma maintains license agreements with Pfizer, Inc. and sub-license agreements with partners including Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, and Knight Therapeutics, Inc.

Puma's annual revenue moved from $253.2M in FY2021 to $228.4M in FY2025, reflecting a 5-year compound annual growth rate of 0.3%. Despite revenue falling 0.9% in FY2025, operating margin improved to 16.3%, and net income reached $31.1M, up from a net loss of -$29.1M in FY2021. Gross margin remained steady, registering 74.5% in FY2025 compared to 74.8% in FY2021. Over the trailing twelve months, revenue reached $231.2M with a profit margin of 11.6% and diluted EPS of $0.51. In the latest quarter ended June 30, 2026, quarterly revenue grew 7.8% year-over-year, while quarterly earnings expanded 35.8%.

As of June 30, 2026, Puma Biotechnology held $93.9M in cash and short-term investments against $4.8M in total debt, yielding net cash of $89.1M. Its current ratio stood at 2.91, and its debt-to-equity ratio was 0.03 alongside shareholders' equity of $138.5M and total assets of $192.7M. In FY2025, operating cash flow was $41.8M and free cash flow was $41.7M, while capital expenditures were limited to $71,000. Over five years, the company's share count increased 28.1%.

Trading at $9.83 on October 16, 2026, Puma Biotechnology carries a market capitalization of $507.4M and an enterprise value of $390.2M. The stock trades at a trailing P/E of 19.3x, a forward P/E of 3.5x, and an EV/EBITDA of 8.6x, below the median of its US-listed Healthcare peers at 24.6x, 17.3x, and 12.0x, respectively. Its price-to-sales multiple is 2.2x versus the peer median of 4.1x. Over the past year, Puma gained 81.7%, outperforming the S&P 500 return of 16.8%, though its 5-year return of 62.5% trailed the index's 83.0%.

A single analyst covers Puma Biotechnology, setting a mean price target of $6.00, which sits 39.0% below the last close of $9.83. For the current fiscal year ending December 31, 2026, EPS is estimated at $0.55, representing a decline of 26.7%, before dropping further to $0.35 in the next fiscal year. Despite projected earnings declines, Puma beat EPS expectations in each of the last 4 quarters. The company's next earnings report is scheduled for November 5, 2026.

This page is an AI-written research summary of Puma Biotechnology, Inc. (PBYI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PBYI income statement, PBYI balance sheet, PBYI key metrics, PBYI analyst forecast, PBYI chart. See the PBYI stock overview for the latest quote and news.